Edgewise Therapeutics (Edgewise Therapeutics (EWTX)) dropped some encouraging data on Tuesday from its Phase 2 CIRRUS-HCM trial, and if you've been following the biotech space, this is the kind of news that makes you sit up a little straighter. The company is testing EDG-7500, an oral cardiac sarcomere modulator, in patients with hypertrophic cardiomyopathy (HCM) — a genetic condition where the heart muscle thickens, making it harder for the heart to pump blood and potentially leading to heart failure or sudden cardiac death. It's a serious condition, and the current treatment options are limited.

The results come from the 12-week Part D cohort, which enrolled 53 patients: 20 with obstructive HCM (oHCM) and 33 with the nonobstructive form (nHCM). The study was designed to inform a future Phase 3 trial, and the data so far look pretty solid.

Obstructive HCM: Big Wins on Multiple Fronts

For patients with obstructive HCM, EDG-7500 delivered significant reductions in left ventricular outflow tract gradient (LVOT-G) — that's the pressure difference across the heart's main pumping chamber — both at rest and after the Valsalva maneuver. The company says 90% of patients showed improvement in these hemodynamic measures. That's a strong signal.

But it's not just about plumbing. The drug also improved heart failure severity markers. Nearly three-quarters of oHCM patients either achieved normal NT-proBNP levels (a key biomarker for heart failure) or recorded at least a 50% reduction from baseline. And patient-reported outcomes improved too: 70% of patients moved up by at least one New York Heart Association functional class, which is a standard way of measuring how much heart failure limits daily activities.

Nonobstructive HCM: Similar Benefits

The nonobstructive group also saw meaningful improvements. EDG-7500 generated an average 65% reduction in NT-proBNP levels, and 88% of patients achieved either normalized levels or at least a 50% reduction. Symptom improvements were also reported, with a 13-point mean increase in some patient-reported measure and 64% achieving at least one class improvement in NYHA status. Diastolic function — how well the heart relaxes between beats — also got better.

Safety: Clean Enough to Move Forward

Edgewise said EDG-7500 was generally well tolerated, with no new safety signals among the 53 patients. Most adverse events were mild to moderate. Importantly, there were no meaningful changes in left ventricular ejection fraction (a measure of how much blood the heart pumps out with each beat), and no cases where ejection fraction fell below 50%. Two cases of new-onset atrial fibrillation were reported, but investigators determined both were unrelated to the study drug.

This safety profile is crucial because some other drugs in this space have raised concerns about reducing heart function too much. EDG-7500 seems to avoid that trap.

The Bigger Picture: A Sharper Focus

Just two weeks ago, Edgewise agreed to sell its muscular dystrophy business to Servier for $1.55 billion upfront and up to $1.1 billion in additional milestone payments. That deal meaningfully strengthens the company's balance sheet and sharpens its focus on the cardiovascular pipeline — with EDG-7500 as the lead candidate. So this positive data comes at a perfect time, giving investors a clearer picture of what Edgewise is betting on.

As of Tuesday's close, Edgewise shares were down 2.58% at $34.29, which might seem odd given the good news. But biotech stocks often trade on expectations, and the market may have already priced in some of this data. Still, for a company that just cashed a $1.55 billion check and now has a promising heart drug with clean safety data, the future looks a lot brighter than a thick heart muscle.